久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

USEUROPEAFRICAASIA 中文雙語Fran?ais
China
Home / China / Business

R&D: the right chemistry?

By Liu Jie | China Daily | Updated: 2012-01-09 07:07

R&D: the right chemistry?

A pharmaceutical exhibition in Nanjing, Jiangsu province. An increasing number of multinational pharmaceutical companies are eyeing the Chinese market as part of their global R&D chains. An Xin / for China Daily

R&D: the right chemistry?

A pharmaceutical exhibition in Shanghai. The increase in cooperation between foreign and domestic companies in R&D is a win-win solution, according to analysts. Shen Jingwei / for China Daily

Overseas pharmaceutical firms are conducting more research in China as the country's medical market expands and the West's health sector shrinks

NANJING - It took preliminary talks lasting more than a year, innumerable onsite investigations and seemingly endless negotiations, but all the effort ultimately led to a contract covering hundreds of pages.

That intensive groundwork resulted in cooperation between the international pharmaceutical company Bristol-Myers Squibb Co (BMS) and the Jiangsu-based Simcere Pharmaceutical Group, who in December 2010 reached a strategic partnership to co-develop an oncology compound (the creation and development of a cancer treatment).

One year later, with research and development (R&D) into the compound still at an early stage, BMS announced that it will expand the strategic partnership to tap a new area - cardiovascular diseases.

Unlike their previous sales-centered strategies, an increasing number of multinational pharmaceutical companies are eyeing the Chinese market as part of their efforts to boost their global R&D chains.

In 2011, BMS also established R&D collaborations with Wuxi AppTec Co Ltd for stability studies into small-molecule new-chemical entities and with Crown Bioscience Inc on the development of cancer treatments.

BMS is not the only international drugmaker actively seeking R&D cooperation with Chinese companies. A number of overseas businesses have enthusiastically embraced the idea of conducting joint R&D, especially with biopharmaceutical companies.

Pfizer Inc, the world's largest drugmaker by sales, has entered into collaboration with MicuRx Pharmaceuticals Inc, a Chinese biopharmaceutical company specializing in the development of antibiotics to treat drug-resistant bacteria, and with Cumencor Pharmaceuticals Inc to discover therapeutic agents for multi-drug-resistant tuberculosis (MDR-TB).

Merck Sharp & Dohme Corp (MSD) - known in the United States and Canada as Merck & Co, the world's second-largest drug producer by sales - recently reached a deal with Shenzhen-based BGI (formerly known as Beijing Genome Institute) to combine the research institute's sequencing and bioinformatics capabilities with MSD's expertise in drug development to identify a new generation of personalized therapies.

Chinese companies will benefit from collaborative partnerships with the multinationals that are exploring new approaches to advancing the clinical development of innovative products in China, on sound molecular pipelines (the number of products under development), extensive experience in R&D management, strong funding support and global R&D resources, said Guo Fanli, an analyst from China Investment Consulting Co Ltd.

Meanwhile, international drugmakers may benefit from rich clinical trial resources, locally tailored products for Chinese patients, technological support for their global R&D networks, cost reductions and easier access to registration and approval, Guo said.

However, challenges exist for both sides, such as cultural differences, analysts said.

Moving to China

Flat demand for medicines and the sluggish economic conditions in developed markets have prompted many multinationals to move their R&D activities to China.

Pfizer closed its R&D facility in the United Kingdom in early 2011, resulting in job losses for more than 2,400 engineers. Meanwhile, Novartis International AG announced in April 2011 that it will cut nearly 550 jobs at its UK R&D center by 2014. Both companies have recently increased their R&D capabilities in China. Pfizer set up its second facility in Wuhan, in Hubei province, in October, to complement an earlier facility in Shanghai. The new unit, where 200 staff will be employed by the end of this year, is also a platform for Pfizer to conduct cooperation with local companies, academic institutes and universities.

At the end of 2010, Novartis AG said it would invest $1 billion in China within five years to enhance its R&D strength in cancer treatments, and its local partners will be engaged in helping to increase efficiency in the research and commercialization of the products.

According to Liu Xue, a professor at the Guanghua School of Management at Peking University, the comparative slowdown in sales of medicines in developed markets means that it makes little economic sense to continue R&D investment in those countries.

According to the international healthcare market researcher IMS Health Inc, China became the world's third-largest pharmaceutical market in 2010. Sales of medicines are predicted to grow 25 to 27 percent year-on-year to exceed $50 billion in 2011. The researcher forecast that the market will grow at an average annual rate of 20.1 percent to reach 694 billion yuan ($110 billion) by 2015.

Apart from the size of the market, foreign companies are also drawn by China's rapidly improving R&D environment, said Liu, adding that cooperation with local partners allows companies to develop locally tailored products and make it easier for them to get industry registration and approval for their research activities.

The biopharmaceutical industry is one of seven strategic sectors for which the Chinese government has promised support in its 12th Five-Year Plan (2011-2015). The country, with the goal of becoming a major research hub in the international pharmaceutical sector, has already allocated 105 billion yuan to key drug-creation programs, launched to support local R&D projects with a view to developing 30 new treatments in 10 major therapeutic areas by 2020.

That government support has prompted overseas companies to further tap into the sector. However, Lydia Xu, a researcher on the pharmaceutical sector with the Samsung Economic Research Institute, said that the majority of the funds will be invested in State-owned researchers or academic institutes and universities.

Although cooperation with Chinese companies will not allow multinationals to access the funding, the domestic environment, which favors biopharmaceutical development, is a bonus in obtaining registration and commercialization approvals for treatments, analysts said.

Jean-Christophe Pointeau, president of BMS China, said that the company had to take registration and approval issues into consideration. Meanwhile, the higher price of self-developed drugs in the Chinese market was also an important element when the company decided to focus on self-developed medicines rather than high-quality generic products.

The ongoing reforms to China's healthcare system have focused on lowering drug prices and healthcare costs in general. Prices should be lower for generic drugs, because they require no technological innovation. However, "for a new innovation-originated product or a specific therapy for a serious disease, for example cancer, a higher price is acceptable, because the cost of R&D is high and it (the medicine) can save lives and bring benefits to the public", said Pointeau.

Common interest

Simcere's President Zhang Yehong said that the cooperation with BMS is based on mutual trust and common interests. Mark Pavao, president of BMS Emerging Markets and Global Access, said the partnership is exciting and hopefully will be a win-win situation.

"We have been committed to building up our R&D capability and are willing to invest significant financial and human resources (in China)," said Zhang, adding that Simcere invests between 7 and 8 percent of its sales in R&D every year.

Founded in 1995, the company now has almost 4,000 employees, with one-tenth of them working in R&D.

"Simcere is a leading Chinese company, a listed company (on the New York Stock Exchange) and very active in global partnership discussions," said Pavao. "We are pursuing 'selective integration' when choosing partners."

Regarding the company's second cooperative project in China, he said: "Our experience over the past year is that everything Simcere said they would do, they have done, ahead of schedule and with very high quality results, which made our companies think maybe we should talk about another one (project)."

According to the agreement, Simcere will receive exclusive rights to develop and commercialize the molecules in China, while BMS will retain exclusive rights in all other markets. The companies will jointly determine their strategic development plan to explore the potential of compounds to treat diseases.

At present, BMS provides molecules for Simcere. "Simcere will provide development expertise and resources to collect high-quality data, data that will stand up to potential applications around the world," said Pavao.

Some observers have said that BMS has an unfair advantage when cooperating with its Chinese partner: All intellectual property rights and income outside China will go to the overseas company, while the Chinese side is responsible for the whole R&D process, including financial investment and human resources.

However, Simcere's Zhang said he doesn't think the deal is skewed in favor of the overseas companies. "R&D collaboration is very complicated. Besides visible contributions, such as funds, equipment and human resources, there are many invisible things, such as the value of self-developed molecules, global resources and technological support," he said.

Zhang added that if a product is commercialized, Simcere will receive a "certain amount" of the revenue BMS generates from the medicine outside China, and in exchange, BMS will enjoy similar rights.

For many multinationals, their strong point is in early-stage molecular discovery, which requires a huge amount of money and can take decades of lab research. These relatively young Chinese biopharmaceutical companies can hardly be expected to discover those molecules by themselves, said Xu.

As a leading global biopharmaceutical company, BMS invests approximately 20 percent of its sales in R&D every year. Xu said that China has an advantage when it comes to clinical trials, because of the huge number of patients and the high standard of its R&D staff.

Challenges ahead

Biopharmaceutical development requires huge investment and carries high risks.

"What is important for people to understand is that each new drug costs approximately $1 billion and it takes an average of 12 years to develop a molecule into a medicine," said Chris H. Lee, president and CEO of Bayer HealthCare China, in an earlier interview.

"During the process, scientists filter the ideal drug out of millions of potential candidates, before selecting suitable candidates for clinical trials. Ultimately, only 5 to 10 percent of clinical candidates will receive regulatory approval," he said.

Many Chinese biopharmaceutical companies are very young and don't have the resources to devote to long-term development with huge investment, not to speak of shouldering the risk of the high possibility of failure, Liu said.

In collaboration with BMS, the foreign company has the resources for the molecular pipeline in its laboratory, but it does not have the resources for further development. "Partnering with us, they offer their early-stage technology and we focus on the next step, and our involvement greatly increases the possibility of success and reduces the risk of failure," said Zhang.

Cultural differences are also regarded as a potential hindrance for Sino-foreign R&D cooperation, Xu said.

There is a State-level biotech and pharmaceutical industrial base in Zhangjiang, Shanghai, which is known as China's "Drug Valley" and plays host to more than 100 drugmakers, including AstraZeneca Plc, Eli Lilly and Company and GlaxoSmithKline PLC as well as professional research institutions. Many of them have ongoing collaborative operative projects.

The administration committee at the Zhangjiang base has taken a number of measures - including hosting technology-transfer fairs, setting up specific departments to work as intermediary agencies and simplifying customs procedures for R&D equipment and biosample imports - to support partnerships between local institutions and foreign companies.

"It's a good way for Chinese academic institutions and enterprises to obtain funds to conduct more research and for foreign drugmakers to get reliable local resources to speed up their R&D in Zhangjiang," said Wang Lanzhong, general manager of the administration committee at the base.

Wang also said the heavy financial costs and long developmental period, coupled with the high failure rate in pharmaceutical R&D, have resulted in more than 500 local enterprises and institutions in Zhangjiang closing or moving out in the past decade.

Meanwhile, some projects don't last the agreed duration, mainly because the foreign and Chinese sides have different management ideologies and cannot compromise, said Liu, highlighting the importance of detailed and accurate contracts in addition to mutual understanding and communications.

"As market conditions continue to change, especially in China, where everything develops quickly, the partners should follow the changes and discuss appropriate responses, and then adjust their operations accordingly," Liu added.

However, Simcere's Zhang said he does not think the differences between Chinese and foreign cultures constitute a problem. "Cultural differences exist in all companies. There are differences between different multinational companies as between local companies. If two partners share the same philosophy and commitment, the problem will not be a problem at all."

Zhang received his college and business education in the United States. He worked for Merck for 12 years and served as the company's China president between 2007 and 2008. With experience in international consulting firms IMS Healthcare and McKinsey & Company, Zhang is knowledgeable about the Western style of business and the condition of China's pharmaceutical industry.

The pursuit of internationalization by Chinese companies and the sluggish market in Western nations have resulted in many Chinese professionals returning from overseas to work for local companies. These people - usually open-minded, flexible and with good professional training - are becoming the backbone of cooperative projects. These human-resource flows can help narrow the cultural gap between Chinese and foreign companies to some extent, said Liu.

"Good partnership means finding good partners. For BMS, finding good partners means finding someone who has good science, focuses on innovation and has the ability to conduct general scientific work," said Pavao.

"If any Chinese company wants to be innovation-oriented and R&D-focused in looking for treatments for serious diseases, we may have an interest in partnering with them," Pointeau said, signaling that BMS China is open to domestic companies while insisting on "selective integration".

China Daily

R&D: the right chemistry?

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    亚洲成人综合在线| 狠狠色狠狠色综合系列| 在线综合+亚洲+欧美中文字幕| 视频一区二区欧美| 欧美大片顶级少妇| 国产ts人妖一区二区| 亚洲欧洲精品一区二区精品久久久 | 九色综合狠狠综合久久| 国产校园另类小说区| 99视频有精品| 同产精品九九九| 国产网红主播福利一区二区| 一本大道久久a久久综合婷婷| 日本人妖一区二区| 国产精品视频一二三| 欧美丝袜第三区| 国产主播一区二区三区| 亚洲乱码国产乱码精品精的特点| 欧美另类一区二区三区| 国产精品影音先锋| 一区二区三区国产豹纹内裤在线| 日韩欧美一级特黄在线播放| 成人h精品动漫一区二区三区| 亚洲v中文字幕| 国产欧美一区二区精品秋霞影院| 欧洲视频一区二区| 国产永久精品大片wwwapp| 玉足女爽爽91| 欧美精品一区二区三区很污很色的 | 9191成人精品久久| 成人免费av网站| 日韩av二区在线播放| 国产精品久久久久久久久免费樱桃| 欧美丰满一区二区免费视频| 成人av在线看| 久久精品国产色蜜蜜麻豆| 亚洲欧美日韩中文字幕一区二区三区| 日韩一区二区三区观看| 91片黄在线观看| 国产伦精一区二区三区| 亚洲图片欧美视频| 欧美国产一区二区| 日韩一卡二卡三卡国产欧美| 色综合亚洲欧洲| 国产成人综合亚洲网站| 首页欧美精品中文字幕| 亚洲欧美国产三级| 久久精品亚洲精品国产欧美| 欧美精品v日韩精品v韩国精品v| jiyouzz国产精品久久| 精品在线播放午夜| 亚洲va国产va欧美va观看| 中文字幕在线不卡一区| 精品美女一区二区| 欧美精品 日韩| 色哟哟在线观看一区二区三区| 国产精品资源站在线| 免费观看久久久4p| 亚洲成人在线免费| 亚洲欧洲性图库| 国产日韩欧美高清| 日韩一区二区三区免费观看| 欧美天堂一区二区三区| 91首页免费视频| 国产成人亚洲综合色影视| 麻豆精品一区二区av白丝在线| 亚洲一二三四区不卡| 亚洲欧美一区二区视频| 国产丝袜美腿一区二区三区| 日韩欧美高清在线| 欧美顶级少妇做爰| 欧美日韩精品是欧美日韩精品| 91麻豆自制传媒国产之光| 成人午夜在线免费| 国产夫妻精品视频| 国产精品影视网| 久久99国产精品久久99| 日本亚洲免费观看| 天堂蜜桃一区二区三区| 亚洲成人av一区二区| 亚洲老司机在线| 亚洲人成在线播放网站岛国| 国产精品视频一二三| 国产日韩欧美一区二区三区乱码| 精品久久久久久久久久久院品网| 日韩欧美国产一二三区| 日韩一区二区三区精品视频| 日韩一区二区三| 欧美一级片免费看| 欧美一区日本一区韩国一区| 91精品国模一区二区三区| 欧美久久久久久蜜桃| 欧美精选午夜久久久乱码6080| 欧美主播一区二区三区| 在线观看三级视频欧美| 91精品福利视频| 欧美三级三级三级| 欧美高清www午色夜在线视频| 欧美三区在线观看| 欧美精品自拍偷拍动漫精品| 制服丝袜在线91| 日韩午夜精品电影| 精品国产91乱码一区二区三区| 精品精品国产高清一毛片一天堂| 精品福利二区三区| 国产午夜精品久久久久久免费视| 国产日韩精品一区| 国产精品久久三| 一区二区三区免费在线观看| 亚洲国产综合人成综合网站| 天堂av在线一区| 久久精品免费看| 国产又黄又大久久| 波多野结衣一区二区三区 | 91网站最新网址| 欧美性高清videossexo| 欧美日韩免费视频| 日韩视频中午一区| 久久久噜噜噜久久人人看| 国产精品午夜久久| 亚洲欧洲中文日韩久久av乱码| 亚洲一区二区在线观看视频| 日韩av网站在线观看| 国产一区二区精品久久| av在线播放不卡| 欧美午夜精品电影| 日韩精品一区二区三区中文不卡| 久久九九全国免费| 亚洲精品日韩综合观看成人91| 亚洲电影在线播放| 麻豆国产精品一区二区三区 | 国产成人无遮挡在线视频| 99久久久久免费精品国产| 在线欧美一区二区| 日韩美一区二区三区| 国产精品国产三级国产三级人妇 | 成人午夜大片免费观看| 91老司机福利 在线| 欧美一区二区在线视频| 国产日韩欧美在线一区| 亚洲一级在线观看| 久久99精品久久久久久动态图| 成人毛片老司机大片| 欧美日韩国产综合一区二区三区 | 亚洲精品一区二区精华| 亚洲天堂av老司机| 三级久久三级久久久| 高清视频一区二区| 欧美日韩国产综合一区二区| 久久午夜羞羞影院免费观看| 亚洲人xxxx| 激情久久久久久久久久久久久久久久| 成人一区二区在线观看| 欧美日韩国产电影| 欧美国产97人人爽人人喊| 香蕉成人啪国产精品视频综合网 | 成人一区在线看| 7777精品久久久大香线蕉 | 国产精品第四页| 青青草成人在线观看| 波多野结衣中文字幕一区| 日韩一区二区在线观看| 亚洲视频资源在线| 国产在线精品一区二区不卡了| 在线观看亚洲成人| 久久九九久久九九| 日韩中文字幕麻豆| av动漫一区二区| 欧美电影免费提供在线观看| 日韩一区在线播放| 国内精品国产三级国产a久久| 欧美综合色免费| 中国色在线观看另类| 久久av资源站| 欧美三电影在线| 国产精品久久久久久久久久久免费看| 日韩**一区毛片| 日本高清视频一区二区| 久久亚洲综合色一区二区三区| 亚洲成人一区在线| www.亚洲国产| 国产亚洲一本大道中文在线| 亚洲成av人片观看| 色菇凉天天综合网| 中文字幕va一区二区三区| 美女一区二区视频| 欧美人xxxx| 亚洲综合一区二区精品导航| 成av人片一区二区| 国产亚洲福利社区一区| 老司机精品视频导航| 欧美日韩国产三级| 一区二区在线免费| 成人免费高清视频在线观看| 久久看人人爽人人| 久久国产免费看| 51精品秘密在线观看| 亚洲图片自拍偷拍| 欧洲国内综合视频| 亚洲男人都懂的|